BioCryst Pharmaceuticals
Delaware corporation
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Source: Wikipedia · CC BY-SA 4.0
last observed
Activity Score
0
confidence 60 % · metrics-v1
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
—
not enough monitored evidence
AI Adoption
0
confidence 60 % · metrics-v1
Corporate Change Index
0
confidence 55 % · cci-v1
9 active sensors·2 observations·0 historical changes·0 structured events·historical coverage 100 %·observed since 2026-09-13
Compare BioCryst Pharmaceuticals with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies
